EDIT vs TMO
Editas Medicine Inc (EDIT) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
EDIT currently screens at market cap $375.2M. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the EDIT and TMO stock pages for the full models.
Not investment advice.